SCHEMBL7038115

SCHEMBL7038115

O=C(Nc1ccc(-c2ccsc2)cc1C(=O)O)c1ccc(C(F)(F)F)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IGF2BP2 Q9Y6M1 1/20 0.50
ACMSD Q8TDX5 1/20 0.50
NPC1 O15118 1/20 0.50
RAB9A P51151 1/20 0.50
KMT2A Q03164 1/20 0.50
PLK1 P53350 1/20 0.49
HDAC1 Q13547 2/20 0.48
HDAC2 Q92769 1/20 0.48
ACLY P53396 1/20 0.47
SERPINE1 P05121 2/20 0.47
PPARG P37231 2/20 0.47
PPARA Q07869 1/20 0.47
KCNK2 O95069 3/20 0.46
PPARD Q03181 1/20 0.46
NR1H4 Q96RI1 1/20 0.46
KCNK10 P57789 2/20 0.46
P2RY14 Q15391 2/20 0.46
AKR1C3 P42330 1/20 0.46
AKR1C2 P52895 1/20 0.46
KDM1A O60341 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7038149 0.99 IGF2BP2 (0.49) IGF2BP2ACMSDNPC1RAB9AKMT2A
Lithium Ion SCHEMBL7038144 0.89 PPARG (0.61) ACMSDNPC1RAB9AKMT2AHDAC1
SCHEMBL7035247 0.81 DHODH (0.51) IGF2BP2ACMSDNPC1RAB9AHDAC1
SCHEMBL7038969 0.80 DHODH (0.50) IGF2BP2ACMSDNPC1RAB9AHDAC1
SCHEMBL7038142 0.77 IGF2BP2 (0.54) IGF2BP2ACMSDNPC1RAB9AKMT2A
SCHEMBL7040190 0.76 PPARG (0.56) IGF2BP2NPC1RAB9AKMT2AHDAC1
SCHEMBL6351486 0.76 KCNK2 (0.73) NPC1RAB9AKMT2APLK1SERPINE1
SCHEMBL16496601 0.76 SERPINE1 (0.75) IGF2BP2KMT2ASERPINE1PPARGPPARA
SCHEMBL2274927 0.76 ACLY (0.63) IGF2BP2NPC1RAB9AKMT2AHDAC2
SCHEMBL5671306 0.76 KCNK2 (0.61) IGF2BP2KMT2AHDAC1HDAC2SERPINE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030073862-A1 Compounds BIOVITRUM AB (SE) 2003-04-17 US claimed
WO-2003004458-A1 NEW COMPOUNDS BIOVITRUM AB (SE) 2003-01-16 WO claimed
US-20030073862-A1 Compounds BIOVITRUM AB (SE) 2003-04-17 US disclosed
WO-2003004458-A1 NEW COMPOUNDS BIOVITRUM AB (SE) 2003-01-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030073862-A1 Compounds PPARG, PPARA, PPARD IGF2BP2 1574/4885ACMSD 2296/4885NPC1 1392/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.